Market closed
Generation Bio/$GBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Generation Bio
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Ticker
$GBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
115
Website
Generation Bio Metrics
BasicAdvanced
$35M
-
-$1.98
2.73
-
Price and volume
Market cap
$35M
Beta
2.73
52-week high
$4.65
52-week low
$0.47
Average daily volume
424K
Financial strength
Current ratio
5.503
Quick ratio
5.328
Long term debt to equity
93.446
Total debt to equity
108.533
Management effectiveness
Return on assets (TTM)
-16.34%
Return on equity (TTM)
-91.02%
Valuation
Price to revenue (TTM)
1.728
Price to book
0.4
Price to tangible book (TTM)
0.4
Price to free cash flow (TTM)
-0.378
Growth
Revenue change (TTM)
236.92%
Earnings per share change (TTM)
0.65%
3-year earnings per share growth (CAGR)
-2.26%
What the Analysts think about Generation Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Generation Bio stock.
Generation Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Generation Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Generation Bio News
AllArticlesVideos
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·1 week ago
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
Business Wire·1 month ago
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Generation Bio stock?
Generation Bio (GBIO) has a market cap of $35M as of March 22, 2025.
What is the P/E ratio for Generation Bio stock?
The price to earnings (P/E) ratio for Generation Bio (GBIO) stock is 0 as of March 22, 2025.
Does Generation Bio stock pay dividends?
No, Generation Bio (GBIO) stock does not pay dividends to its shareholders as of March 22, 2025.
When is the next Generation Bio dividend payment date?
Generation Bio (GBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Generation Bio?
Generation Bio (GBIO) has a beta rating of 2.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.